Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JULIET: Tisagenlecleucel in r/r DLBCL
NCT02445248Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2015
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells
- Countries
- 10
01
Overview
A Phase 2 trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Novartis. Started Jul 2015; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02445248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02445248.